Search results for "Quinagolide"

showing 2 items of 2 documents

The effects of ergot and non-ergot-derived dopamine agonists in an experimental mouse model of endometriosis

2011

Implantation of a retrogradely shed endometrium during menstruation requires an adequate blood supply, which allows the growth of endometriotic lesions. This suggests that the development of endometriosis can be impaired by inhibiting angiogenesis. The growth of endometriotic foci is impaired by commercial oncological antiangiogenic drugs used to block vascular endothelial growth factor (VEGF) signaling. The dopamine agonist cabergoline (Cb2) inhibits the growth of established endometriosis lesions by exerting antiangiogenic effects through VEGFR2 inactivation. However, the use of ergot-derived Cb2 is associated with an increased incidence of cardiac valve regurgitation. To evaluate the pot…

Embryologymedicine.medical_specialtyCabergolineProliferation indexAngiogenesisEndometriosisEndometriosisCell CountPharmacologyDopamine agonistClavicepsNeovascularizationEndometriumMicechemistry.chemical_compoundEndocrinologyInternal medicineCabergolinemedicineAnimalsHumansErgolinesCell ProliferationUterine DiseasesNeovascularization PathologicReceptors Dopamine D2business.industryQuinagolideObstetrics and GynecologyCell Biologymedicine.diseaseVascular Endothelial Growth Factor Receptor-2Vascular endothelial growth factorDisease Models AnimalEndocrinologyReproductive MedicinechemistryDopamine AgonistsBlood VesselsFemalemedicine.symptombusinessmedicine.drugREPRODUCTION
researchProduct

Physiology and Pathology of Ovarian Hyperstimulation Syndrome

2010

Ovarian hyperstimulation syndrome (OHSS) occurs when ovaries primed with follicle-stimulating hormone/leuteinizing hormone (LH) are subsequently exposed to human chorionic gonadotropin (hCG). The ultimate pathophysiological step underlying this clinical picture is increased vascular permeability (VP). With the administration of hCG, the expression vascular endothelial growth factor (VEGF) and VEGF receptor 2 (VEGFR-2) mRNA increases significantly rising to a maximum coinciding with peaked VP. Immunohistochemistry shows the presence of VEGF and VEGFR-2 proteins in the granulosa-lutein and endothelial cells of the entire corpus luteum. These findings suggest that the syndrome can be prevented…

Vascular Endothelial Growth Factor AAgonistendocrine systemmedicine.medical_specialtymedicine.drug_classEndocrinology Diabetes and MetabolismOvarian hyperstimulation syndromeBiologyModels BiologicalDopamine agonistHuman chorionic gonadotropinOvarian Hyperstimulation SyndromeEndocrinologyOvulation InductionPregnancyPhysiology (medical)Internal medicineCabergolinemedicineAnimalsHumansLeuteinizing hormoneQuinagolideObstetrics and GynecologyFertility Agents Femalemedicine.diseaseVascular Endothelial Growth Factor Receptor-2medicine.anatomical_structureEndocrinologyReproductive MedicineDopamine AgonistsFemaleCorpus luteummedicine.drugSeminars in Reproductive Medicine
researchProduct